Phrontline raises $40M Series A for bispecific ADC cancer drugs
What's the deal? Phrontline Biopharma has raised a $40 million Series A round to advance its antibody-drug conjugate (ADC) programs for cancer. Yuanhe OriginDealroom has a profile for this one. Try Dealroom → and TCGXDealroom has a profile for this one. Try Dealroom → co-led the round, with Highlight CapitalDealroom has a profile for this one. Try Dealroom →, C&D Emerging Industry Investment, Songqing Private Fund, Miramed Health Fund, Longpan InvestmentDealroom has a profile for this one. Try Dealroom →, and others participating.
What's the endgame? The company develops ADCs built on two platforms: bispecific antibodies to improve targeting precision, and a dual-payload design meant to overcome tumour resistance and extend treatment response. Its lead program, TJ101, is an EGFR/B7-H3 bispecific ADC.
Why now? Phrontline says TJ101 has begun clinical enrolment in both China and the US. The funding will support its bispecific ADC and dual-payload ADC research.
What could go wrong? This is an early-stage bet. The round provides capital to push a differentiated ADC platform through the clinic, but it does not prove the candidates will work or reach the market.
The signal: The raise tracks rising interest in Chinese oncology assets. Chinese biotech firms took part in more than half of global large drug-licensing deals in the first three quarters of 2026, and Boehringer IngelheimDealroom has a profile for this one. Try Dealroom → recently struck an ADC and T-cell engager partnership with Innovent worth $358 million in upfront and near-term payments. Against those later-stage deals, Phrontline's Series A is an early wager on where that pipeline begins.
Read more: itjuzi.com
Image credit: Generated with Gemini
